Anika Therapeutics Inc. · NASDAQ:ANIK
Anika Therapeutics — Q4 2024 Earnings Presentation
17 slides from Anika Therapeutics's earnings presentation, Mar 12, 2025
Slide 1: Q4 and Year-End 2024 Earnings Call
Q4 AND YEAR-END 2024 EARNINGS CALL MARCH 12, 2025 Anika. Restore Active Living.
Slide 2: Safe Harbor Statements
SAFE HARBOR STATEMENTS Cautionary Note on Forward-looking Statements The statements made in, and during the course of, this presentation that are not statements of historical fact, including those related to the Company’s commercial capabilities, initiatives and production, its product pipeline and
Slide 3: Company Highlights
COMPANY HIGHLIGHTS STRONG EXECUTION DELIVERING RESULTS ON STRATEGIC PRIORITIES Commercial Execution Pipeline Development Company Transformation • 40%+ sequential growth for • Second module of Hyalofast® PMA • Completed sale of Parcus Medical Integrity Implant System for 3rd filed in January 2025 con
Slide 4: Q4 2024 Financial Highlights
Q4 2024 FINANCIAL HIGHLIGHTS CONTINUING DISCONTINUED TOTAL $M, except per share data OPERATIONS OPERATIONS COMPANY 4Q24 Continuing Operations Highlights Q4 Financial Results 2024 VPY 4Q24 4Q24 • Revenue increased by 1% to $30.6M driven by 25% Commercial Channel growth, led by Revenue $30.6 +1% $7.6
Slide 5: Full Year 2024 Financial Highlights
FULL YEAR 2024 FINANCIAL HIGHLIGHTS CONTINUING DISCONTINUED TOTAL $M, except per share data OPERATIONS OPERATIONS COMPANY 2024 Continuing Operations Highlights 2024 Financial Results 2024 VPY 2024 2024 • Revenue decreased 1% to $119.9M driven by +17% Commercial Channel growth led by Revenue $119.9 (
Slide 6: 2025 Guidance
2025 GUIDANCE $M 2021 2022 2023 2024 2025 Est 1 2026 Est 1 2027 Est 1 Commercial Revenue • International OA Pain +17% 3-Year CAGR • Regenerative Solutions • Hyalofast (4Q26-2027) +20-30% $47-49.5 +20-30% $32 $36 $42 +12-18% $26 OEM Revenue • US OA Pain though J&J Lower • Non-Orthopedic Solutions $81
Slide 7: Strategies to Deliver Shareholder Value
3 STRATEGIES TO DELIVER SHAREHOLDER VALUE Near-Term: Deliver market leading OA Pain Management products and achieve full potential of Integrity (2025) Implant System in high-growth $220M tendon augmentation TAM Mid-Term: FDA approval and successful launch of Hyalofast® in Anika’s Commercial Channel
Slide 8: @ ANIKA
@ ANIKA
Slide 9: Non-GAAP Reconciliation and Supplemental Data
NON-GAAP RECONCILIATION AND SUPPLEMENTAL DATA 9
Slide 10: Statement of Operations
STATEMENT OF OPERATIONS @ ANIKA 40
Slide 11: Balance Sheet
BALANCE SHEET @ ANIKA "
Slide 12: Reconciliation Tables – GAAP Gross Profit to Adjusted Gross Profit and Margin
RECONCILIATION TABLES – GAAP GROSS PROFIT TO ADJUSTED GROSS PROFIT AND ADJUSTED GROSS MARGIN 12
Slide 13: Reconciliation Tables – GAAP Net Income to Adjusted EBITDA
RECONCILIATION TABLES – GAAP NET INCOME TO ADJUSTED EBITDA 13
Slide 14: Reconciliation Tables – GAAP Net Income to Adjusted Net Income
RECONCILIATION TABLES – GAAP NET INCOME TO ADJUSTED NET INCOME Note: Beginning in Q1-2024, adjusted net income and adjusted EPS were revised to exclude stock-based compensation expense, net of tax, and this revised calculation is reflected for all periods presented. 14
Slide 15: Reconciliation Tables – GAAP EPS to Adjusted EPS
RECONCILIATION TABLES – GAAP EPS TO ADJUSTED EPS Note: Beginning in Q1-2024, adjusted net income and adjusted EPS were revised to exclude stock-based compensation expense, net of tax, and this revised calculation is reflected for all periods presented. 15
Slide 16: Revenue by Channel
REVENUE BY CHANNEL @ ANIKA 16
Slide 17: @ ANIKA
@ ANIKA